1
|
Wesdorp NJ, Zeeuw JM, Postma SCJ, Roor J, van Waesberghe JHTM, van den Bergh JE, Nota IM, Moos S, Kemna R, Vadakkumpadan F, Ambrozic C, van Dieren S, van Amerongen MJ, Chapelle T, Engelbrecht MRW, Gerhards MF, Grunhagen D, van Gulik TM, Hermans JJ, de Jong KP, Klaase JM, Liem MSL, van Lienden KP, Molenaar IQ, Patijn GA, Rijken AM, Ruers TM, Verhoef C, de Wilt JHW, Marquering HA, Stoker J, Swijnenburg RJ, Punt CJA, Huiskens J, Kazemier G. Deep learning models for automatic tumor segmentation and total tumor volume assessment in patients with colorectal liver metastases. Eur Radiol Exp 2023; 7:75. [PMID: 38038829 PMCID: PMC10692044 DOI: 10.1186/s41747-023-00383-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 09/08/2023] [Indexed: 12/02/2023] Open
Abstract
BACKGROUND We developed models for tumor segmentation to automate the assessment of total tumor volume (TTV) in patients with colorectal liver metastases (CRLM). METHODS In this prospective cohort study, pre- and post-systemic treatment computed tomography (CT) scans of 259 patients with initially unresectable CRLM of the CAIRO5 trial (NCT02162563) were included. In total, 595 CT scans comprising 8,959 CRLM were divided into training (73%), validation (6.5%), and test sets (21%). Deep learning models were trained with ground truth segmentations of the liver and CRLM. TTV was calculated based on the CRLM segmentations. An external validation cohort was included, comprising 72 preoperative CT scans of patients with 112 resectable CRLM. Image segmentation evaluation metrics and intraclass correlation coefficient (ICC) were calculated. RESULTS In the test set (122 CT scans), the autosegmentation models showed a global Dice similarity coefficient (DSC) of 0.96 (liver) and 0.86 (CRLM). The corresponding median per-case DSC was 0.96 (interquartile range [IQR] 0.95-0.96) and 0.80 (IQR 0.67-0.87). For tumor segmentation, the intersection-over-union, precision, and recall were 0.75, 0.89, and 0.84, respectively. An excellent agreement was observed between the reference and automatically computed TTV for the test set (ICC 0.98) and external validation cohort (ICC 0.98). In the external validation, the global DSC was 0.82 and the median per-case DSC was 0.60 (IQR 0.29-0.76) for tumor segmentation. CONCLUSIONS Deep learning autosegmentation models were able to segment the liver and CRLM automatically and accurately in patients with initially unresectable CRLM, enabling automatic TTV assessment in such patients. RELEVANCE STATEMENT Automatic segmentation enables the assessment of total tumor volume in patients with colorectal liver metastases, with a high potential of decreasing radiologist's workload and increasing accuracy and consistency. KEY POINTS • Tumor response evaluation is time-consuming, manually performed, and ignores total tumor volume. • Automatic models can accurately segment tumors in patients with colorectal liver metastases. • Total tumor volume can be accurately calculated based on automatic segmentations.
Collapse
Affiliation(s)
- Nina J Wesdorp
- Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.
| | - J Michiel Zeeuw
- Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.
| | - Sam C J Postma
- Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands
| | - Joran Roor
- Department of Health, SAS Institute B.V, Huizen, the Netherlands
| | - Jan Hein T M van Waesberghe
- Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - Janneke E van den Bergh
- Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - Irene M Nota
- Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - Shira Moos
- Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - Ruby Kemna
- Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands
| | - Fijoy Vadakkumpadan
- Department of Computer Vision and Machine Learning, SAS Institute Inc, Cary, NC, USA
| | - Courtney Ambrozic
- Department of Computer Vision and Machine Learning, SAS Institute Inc, Cary, NC, USA
| | - Susan van Dieren
- Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands
| | | | - Thiery Chapelle
- Department of Hepatobiliary, Transplantation, and Endocrine Surgery, Antwerp University Hospital, Antwerp, Belgium
| | - Marc R W Engelbrecht
- Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | | | - Dirk Grunhagen
- Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
| | - Thomas M van Gulik
- Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands
| | - John J Hermans
- Department of Medical Imaging, Radboud University Medical Center, Radboud University Nijmegen, Nijmegen, the Netherlands
| | - Koert P de Jong
- Department of HPB Surgery and Liver Transplantation, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - Joost M Klaase
- Department of HPB Surgery and Liver Transplantation, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - Mike S L Liem
- Department of Surgery, Medical Spectrum Twente, Enschede, the Netherlands
| | - Krijn P van Lienden
- Department of Interventional Radiology, St Antonius Hospital, Nieuwegein, the Netherlands
| | - I Quintus Molenaar
- Department of Surgery, Regional Academic Cancer Center Utrecht, University Medical Center Utrecht, Utrecht, the Netherlands
- Department of Surgery, St Antonius Hospital, Nieuwegein, the Netherlands
| | - Gijs A Patijn
- Department of Surgery, Isala Hospital, Zwolle, the Netherlands
| | - Arjen M Rijken
- Department of Surgery, Amphia Hospital, Breda, the Netherlands
| | - Theo M Ruers
- Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands
| | - Cornelis Verhoef
- Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
| | - Johannes H W de Wilt
- Department of Surgery, Radboud University Medical Center, Radboud University Nijmegen, Nijmegen, the Netherlands
| | - Henk A Marquering
- Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- Department of Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| | - Jaap Stoker
- Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - Rutger-Jan Swijnenburg
- Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands
| | - Cornelis J A Punt
- Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Joost Huiskens
- Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands
| | - Geert Kazemier
- Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands
| |
Collapse
|
2
|
Zhang J, Luo S, Qiang Y, Tian Y, Xiao X, Li K, Li X. Edge Constraint and Location Mapping for Liver Tumor Segmentation from Nonenhanced Images. COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE 2022; 2022:1248311. [PMID: 35309832 PMCID: PMC8926519 DOI: 10.1155/2022/1248311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/25/2021] [Revised: 02/14/2022] [Accepted: 02/16/2022] [Indexed: 11/18/2022]
Abstract
As there is no contrast enhancement, the liver tumor area in nonenhanced MRI exists with blurred edges and low contrast, which greatly affects the speed and accuracy of liver tumor diagnosis. As a result, precise segmentation of liver tumor from nonenhanced MRI has become an urgent and challenging task. In this paper, we propose an edge constraint and localization mapping segmentation model (ECLMS) to accurately segment liver tumor from nonenhanced MRI. It consists of two parts: localization network and dual-branch segmentation network. We build the localization network, which generates prior coarse masks to provide position mapping for the segmentation network. This part enhances the ability of the model to localize liver tumor in nonenhanced images. We design a dual-branch segmentation network, where the main decoding branch focuses on the feature representation in the core region of the tumor and the edge decoding branch concentrates on capturing the edge information of the tumor. To improve the ability of the model for capturing detailed features, sSE blocks and dense upward connections are introduced into it. We design the bottleneck multiscale module to construct multiscale feature representations using kernels of different sizes while integrating the location mapping of tumor. The ECLMS model is evaluated on a private nonenhanced MRI dataset that comprises 215 different subjects. The model achieves the best Dice coefficient, precision, and accuracy of 90.23%, 92.25%, and 92.39%, correspondingly. The effectiveness of our model is demonstrated by experiment results, and our model reaches superior results in the segmentation task of nonenhanced liver tumor compared to existing segmentation methods.
Collapse
Affiliation(s)
- Jina Zhang
- College of Information and Computer, Taiyuan University of Technology, Taiyuan, China
| | - Shichao Luo
- College of Information and Computer, Taiyuan University of Technology, Taiyuan, China
| | - Yan Qiang
- College of Information and Computer, Taiyuan University of Technology, Taiyuan, China
| | - Yuling Tian
- College of Information and Computer, Taiyuan University of Technology, Taiyuan, China
| | - Xiaojiao Xiao
- College of Information and Computer, Taiyuan University of Technology, Taiyuan, China
| | - Keqin Li
- Department of Computer Science, State University of New York, New Paltz, New York 12561, USA
| | - Xingxu Li
- College of Information and Computer, Taiyuan University of Technology, Taiyuan, China
| |
Collapse
|
3
|
Yang Y, Zou X, Zhou W, Yuan G, Hu D, Shen Y, Xie Q, Zhang Q, Kuang D, Hu X, Li Z. DWI-based radiomic signature: potential role for individualized adjuvant chemotherapy in intrahepatic cholangiocarcinoma after partial hepatectomy. Insights Imaging 2022; 13:37. [PMID: 35244793 PMCID: PMC8897536 DOI: 10.1186/s13244-022-01179-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2021] [Accepted: 02/07/2022] [Indexed: 11/10/2022] Open
Abstract
Objectives To develop a diffusion-weighted imaging (DWI) based radiomic signature for predicting early recurrence (ER) (i.e., recurrence within 1 year after surgery), and to explore the potential value for individualized adjuvant chemotherapy. Methods A total of 124 patients with intrahepatic cholangiocarcinoma (ICC) were randomly divided into the training (n = 87) and the validation set (n = 37). Radiomic signature was built using radiomic features extracted from DWI with random forest. An integrated radiomic nomogram was constructed with multivariate logistic regression analysis to demonstrate the incremental value of the radiomic signature beyond clinicopathological-radiographic factors. A clinicopathological-radiographic (CPR) model was constructed as a reference. Results The radiomic signature showed a comparable discrimination performance for predicting ER to CPR model in the validation set (AUC, 0.753 vs. 0.621, p = 0.274). Integrating the radiomic signature with clinicopathological-radiographic factors further improved prediction performance compared with CPR model, with an AUC of 0.821 (95%CI 0.684–0.959) in the validation set (p = 0.01). The radiomic signature succeeded to stratify patients into distinct survival outcomes according to their risk index of ER, and remained an independent prognostic factor in multivariable analysis (disease-free survival (DFS), p < 0.0001; overall survival (OS), p = 0.029). Furthermore, adjuvant chemotherapy improved prognosis in high-risk patients defined by the radiomic signature (DFS, p = 0.029; OS, p = 0.088) and defined by the nomogram (DFS, p = 0.031; OS, p = 0.023), whereas poor chemotherapy efficacy was detected in low-risk patients. Conclusions The preoperative DWI-based radiomic signature could improve prognostic prediction and help to identify ICC patients who may benefit from postoperative adjuvant chemotherapy. Supplementary Information The online version contains supplementary material available at 10.1186/s13244-022-01179-7.
Collapse
Affiliation(s)
- Yang Yang
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, 430030, Hubei, China
| | - Xianlun Zou
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, 430030, Hubei, China
| | - Wei Zhou
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, 430030, Hubei, China
| | - Guanjie Yuan
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, 430030, Hubei, China
| | - Daoyu Hu
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, 430030, Hubei, China
| | - Yaqi Shen
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, 430030, Hubei, China
| | - Qingguo Xie
- Department of Biomedical Engineering, Huazhong University of Science and Technology, 430074, Wuhan, Hubei, China
| | - Qingpeng Zhang
- School of Data Science, City University of Hong Kong, Kowloon, Hong Kong, China
| | - Dong Kuang
- Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, 430030, Hubei, China.
| | - Xuemei Hu
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, 430030, Hubei, China.
| | - Zhen Li
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, 430030, Hubei, China
| |
Collapse
|
4
|
Balsano C, Alisi A, Brunetto MR, Invernizzi P, Burra P, Piscaglia F. The application of artificial intelligence in hepatology: A systematic review. Dig Liver Dis 2022; 54:299-308. [PMID: 34266794 DOI: 10.1016/j.dld.2021.06.011] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 06/04/2021] [Accepted: 06/07/2021] [Indexed: 02/06/2023]
Abstract
The integration of human and artificial intelligence (AI) in medicine has only recently begun but it has already become obvious that intelligent systems can dramatically improve the management of liver diseases. Big data made it possible to envisage transformative developments of the use of AI for diagnosing, predicting prognosis and treating liver diseases, but there is still a lot of work to do. If we want to achieve the 21st century digital revolution, there is an urgent need for specific national and international rules, and to adhere to bioethical parameters when collecting data. Avoiding misleading results is essential for the effective use of AI. A crucial question is whether it is possible to sustain, technically and morally, the process of integration between man and machine. We present a systematic review on the applications of AI to hepatology, highlighting the current challenges and crucial issues related to the use of such technologies.
Collapse
Affiliation(s)
- Clara Balsano
- Dept. of Life, Health and Environmental Sciences MESVA, University of L'Aquila, Piazza S. Salvatore Tommasi 1, 67100, Coppito, L'Aquila. Italy; Francesco Balsano Foundation, Via Giovanni Battista Martini 6, 00198, Rome, Italy.
| | - Anna Alisi
- Research Unit of Molecular Genetics of Complex Phenotypes, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Maurizia R Brunetto
- Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, University Hospital of Pisa, Pisa, Italy
| | - Pietro Invernizzi
- Division of Gastroenterology and Center of Autoimmune Liver Diseases, Department of Medicine and Surgery, San Gerardo Hospital, University of Milano, Bicocca, Italy
| | - Patrizia Burra
- Multivisceral Transplant Unit, Department of Surgery, Oncology, Gastroenterology, Padua University Hospital, Padua, Italy
| | - Fabio Piscaglia
- Division of Internal Medicine, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy
| | | |
Collapse
|
5
|
Yang Y, Zou X, Zhou W, Yuan G, Hu D, Kuang D, Shen Y, Xie Q, Zhang Q, Hu X, Li Z. Multiparametric MRI-Based Radiomic Signature for Preoperative Evaluation of Overall Survival in Intrahepatic Cholangiocarcinoma After Partial Hepatectomy. J Magn Reson Imaging 2022; 56:739-751. [PMID: 35049076 DOI: 10.1002/jmri.28071] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Revised: 01/05/2022] [Accepted: 01/08/2022] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND The clinical outcomes of patients with intrahepatic cholangiocarcinoma (ICC) after partial hepatectomy remain suboptimal. Identifying patients with poor outcomes before surgery is urgently required. PURPOSE To develop a multiparametric magnetic resonance imaging (MRI)-based radiomic signature to evaluate overall survival (OS) preoperatively and to investigate its incremental value for disease stratification. STUDY TYPE Retrospective. SUBJECTS One hundred and sixty-three patients with pathologically defined ICC, divided into training (N = 115) and validation sets (N = 48). SEQUENCE Three-dimensional T1-weighted gradient-echo sequence with and without contrast agent, T2-weighted fast spin-echo sequence, and diffusion-weighted imaging with single-shot echo-planar sequence at 1.5 T or 3.0 T. ASSESSMENT OS was defined as the time from the date of surgery to death or last contact. The radiomic signature was built based on the least absolute shrinkage and selection operator regression model. A clinicopathologic-radiographic (CPR) model and a combined model integrating radiomic signature with CPR factors were developed with multivariable Cox regression models. STATISTICAL TESTS Harrell's concordance index (C-index) was used to compare the discrimination of different models. Net reclassification index (NRI) and integrated discrimination improvement (IDI) were used to quantify the improvement of prognostic accuracy after adding radiomic signature. RESULTS The high-risk patients of death defined by the radiomic signature showed significantly lower OS compared with low-risk patients in validation set (3-year OS 17.1% vs. 56.4%, P < 0.001). Integrating radiomic signature into tumor, node, and metastasis (TNM) staging system significantly improved the prognostic accuracy compared with TNM stage alone (validation set C-index 0.745 vs. 0.649, P = 0.039, NRI improvement 39.9%-43.8%, IDI improvement 16.1%-19.4%). The radiomic signature showed no significant difference of C-index with postoperative CPR model (validation set, 0.698 vs. 0.674, P = 0.752). Incorporating the radiomic signature into CPR model significantly improved prognostic accuracy (NRI improvement 32.5%-34.3%, IDI improvement 8.1%-12.9%). DATA CONCLUSION Multiparametric MRI-based radiomic signature is a potential biomarker for preoperative prognostic evaluation of ICC patients. LEVEL OF EVIDENCE 4 TECHNICAL EFFICACY: Stage 4.
Collapse
Affiliation(s)
- Yang Yang
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Xianlun Zou
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Wei Zhou
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Guanjie Yuan
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Daoyu Hu
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Dong Kuang
- Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yaqi Shen
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Qingguo Xie
- Department of Biomedical Engineering, Huazhong University of Science and Technology, Wuhan, China
| | - Qingpeng Zhang
- School of Data Science, City University of Hong Kong, Hong Kong, China
| | - Xuemei Hu
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Zhen Li
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
6
|
Qu M, Jia Z, Sun L, Wang H. Diagnostic accuracy of three-dimensional contrast-enhanced ultrasound for focal liver lesions: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021; 100:e28147. [PMID: 34941062 PMCID: PMC8701827 DOI: 10.1097/md.0000000000028147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Accepted: 11/17/2021] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Contrast-enhanced ultrasound (CEUS) examination is a well-established technique for this purpose with several unique advantages. It is a real-time technology with high temporal resolution. With its unique ability to detect microvascular perfusion, it helps in better characterization of FLL.[1-4] Three-dimensional (3D) CEUS with quantitative analysis is updated in recent years. 3D-CEUS is a new ultrasonic diagnostic technique, which can observe the nourishing vessels of lesions from multiple angles. Previous studies showed that 3D-CEUS can detect tumor nourishing vessels to differentiate benign from malignant focal liver lesions (FLLs). However, the results of these studies have been contradictory. Therefore, this meta-analysis tested the hypothesis that 3D-CEUS is accurate in distinguishing benign and malignant FLLs. METHODS We will search PubMed, Web of Science, Cochrane Library, and Chinese biomedical databases from their inceptions to the April 30, 2021, without language restrictions. Two authors will independently carry out searching literature records, scanning titles and abstracts, full texts, collecting data, and assessing risk of bias. Review Manager 5.2 and Stata14.0 software will be used for data analysis. RESULTS This systematic review will determine the accuracy of 3D-CEUS in the differential diagnosis between benign and malignant FLLs. CONCLUSION Its findings will provide helpful evidence for the accuracy of 3D-CEUS in the differential diagnosis between benign and malignant FLLs. SYSTEMATIC REVIEW REGISTRATION INPLASY202150096.
Collapse
|
7
|
Wang B, Yang J, Ai J, Luo N, An L, Feng H, Yang B, You Z. Accurate Tumor Segmentation via Octave Convolution Neural Network. Front Med (Lausanne) 2021; 8:653913. [PMID: 34095168 PMCID: PMC8169966 DOI: 10.3389/fmed.2021.653913] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Accepted: 03/24/2021] [Indexed: 11/13/2022] Open
Abstract
Three-dimensional (3D) liver tumor segmentation from Computed Tomography (CT) images is a prerequisite for computer-aided diagnosis, treatment planning, and monitoring of liver cancer. Despite many years of research, 3D liver tumor segmentation remains a challenging task. In this paper, we propose an effective and efficient method for tumor segmentation in liver CT images using encoder-decoder based octave convolution networks. Compared with other convolution networks utilizing standard convolution for feature extraction, the proposed method utilizes octave convolutions for learning multiple-spatial-frequency features, thus can better capture tumors with varying sizes and shapes. The proposed network takes advantage of a fully convolutional architecture which performs efficient end-to-end learning and inference. More importantly, we introduce a deep supervision mechanism during the learning process to combat potential optimization difficulties, and thus the model can acquire a much faster convergence rate and more powerful discrimination capability. Finally, we integrate octave convolutions into the encoder-decoder architecture of UNet, which can generate high resolution tumor segmentation in one single forward feeding without post-processing steps. Both architectures are trained on a subset of the LiTS (Liver Tumor Segmentation) Challenge. The proposed approach is shown to significantly outperform other networks in terms of various accuracy measures and processing speed.
Collapse
Affiliation(s)
- Bo Wang
- The State Key Laboratory of Precision Measurement Technology and Instruments, Department of Precision Instrument, Tsinghua University, Beijing, China.,Innovation Center for Future Chips, Tsinghua University, Beijing, China.,Beijing Jingzhen Medical Technology Ltd., Beijing, China
| | - Jingyi Yang
- School of Artificial Intelligence, Xidian University, Xi'an, China
| | - Jingyang Ai
- Beijing Jingzhen Medical Technology Ltd., Beijing, China
| | - Nana Luo
- Affiliated Hospital of Jining Medical University, Jining, China
| | - Lihua An
- Affiliated Hospital of Jining Medical University, Jining, China
| | - Haixia Feng
- Affiliated Hospital of Jining Medical University, Jining, China
| | - Bo Yang
- China Institute of Marine Technology & Economy, Beijing, China
| | - Zheng You
- The State Key Laboratory of Precision Measurement Technology and Instruments, Department of Precision Instrument, Tsinghua University, Beijing, China.,Innovation Center for Future Chips, Tsinghua University, Beijing, China
| |
Collapse
|
8
|
Radiomics of Liver Metastases: A Systematic Review. Cancers (Basel) 2020; 12:cancers12102881. [PMID: 33036490 PMCID: PMC7600822 DOI: 10.3390/cancers12102881] [Citation(s) in RCA: 62] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Revised: 10/03/2020] [Accepted: 10/05/2020] [Indexed: 12/15/2022] Open
Abstract
Simple Summary Patients with liver metastases can be scheduled for different therapies (e.g., chemotherapy, surgery, radiotherapy, and ablation). The choice of the most appropriate treatment should rely on adequate understanding of tumor biology and prediction of survival, but reliable biomarkers are lacking. Radiomics is an innovative approach to medical imaging: it identifies invisible-to-the-human-eye radiological patterns that can predict tumor aggressiveness and patients outcome. We reviewed the available literature to elucidate the role of radiomics in patients with liver metastases. Thirty-two papers were analyzed, mostly (56%) concerning metastases from colorectal cancer. Even if available studies are still preliminary, radiomics provided effective prediction of response to chemotherapy and of survival, allowing more accurate and earlier prediction than standard predictors. Entropy and homogeneity were the radiomic features with the strongest clinical impact. In the next few years, radiomics is expected to give a consistent contribution to the precision medicine approach to patients with liver metastases. Abstract Multidisciplinary management of patients with liver metastases (LM) requires a precision medicine approach, based on adequate profiling of tumor biology and robust biomarkers. Radiomics, defined as the high-throughput identification, analysis, and translational applications of radiological textural features, could fulfill this need. The present review aims to elucidate the contribution of radiomic analyses to the management of patients with LM. We performed a systematic review of the literature through the most relevant databases and web sources. English language original articles published before June 2020 and concerning radiomics of LM extracted from CT, MRI, or PET-CT were considered. Thirty-two papers were identified. Baseline higher entropy and lower homogeneity of LM were associated with better survival and higher chemotherapy response rates. A decrease in entropy and an increase in homogeneity after chemotherapy correlated with radiological tumor response. Entropy and homogeneity were also highly predictive of tumor regression grade. In comparison with RECIST criteria, radiomic features provided an earlier prediction of response to chemotherapy. Lastly, texture analyses could differentiate LM from other liver tumors. The commonest limitations of studies were small sample size, retrospective design, lack of validation datasets, and unavailability of univocal cut-off values of radiomic features. In conclusion, radiomics can potentially contribute to the precision medicine approach to patients with LM, but interdisciplinarity, standardization, and adequate software tools are needed to translate the anticipated potentialities into clinical practice.
Collapse
|
9
|
Masokano IB, Liu W, Xie S, Marcellin DFH, Pei Y, Li W. The application of texture quantification in hepatocellular carcinoma using CT and MRI: a review of perspectives and challenges. Cancer Imaging 2020; 20:67. [PMID: 32962762 PMCID: PMC7510095 DOI: 10.1186/s40644-020-00341-y] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Accepted: 08/31/2020] [Indexed: 02/06/2023] Open
Abstract
Recently, radiomic texture quantification of tumors has received much attention from radiologists, scientists, and stakeholders because several results have shown the feasibility of using the technique to diagnose and manage oncological conditions. In patients with hepatocellular carcinoma, radiomics has been applied in all stages of tumor evaluation, including diagnosis and characterization of the genotypic behavior of the tumor, monitoring of treatment responses and prediction of various clinical endpoints. It is also useful in selecting suitable candidates for specific treatment strategies. However, the clinical validation of hepatocellular carcinoma radiomics is limited by challenges in imaging protocol and data acquisition parameters, challenges in segmentation techniques, dimensionality reduction, and modeling methods. Identification of the best segmentation and optimal modeling methods, as well as texture features most stable to imaging protocol variability would go a long way in harmonizing HCC radiomics for personalized patient care. This article reviews the process of HCC radiomics, its clinical applications, associated challenges, and current optimization strategies.
Collapse
Affiliation(s)
- Ismail Bilal Masokano
- Department of Radiology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China
| | - Wenguang Liu
- Department of Radiology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China
| | - Simin Xie
- Department of Radiology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China
| | | | - Yigang Pei
- Department of Radiology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
| | - Wenzheng Li
- Department of Radiology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
| |
Collapse
|
10
|
Bartolotta TV, Sidoti Pinto A, Cannella R, Porrello G, Taravella R, Randazzo A, Taibbi A. Focal liver lesions: interobserver and intraobserver agreement of three-dimensional contrast-enhanced ultrasound-assisted volume measurements. Ultrasonography 2020; 40:333-341. [PMID: 33080667 PMCID: PMC8217797 DOI: 10.14366/usg.20025] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2020] [Accepted: 08/19/2020] [Indexed: 12/11/2022] Open
Abstract
PURPOSE This study was conducted to assess the interobserver and intraobserver agreement of three-dimensional contrast-enhanced ultrasound (3D-CEUS) volume calculations of focal liver lesions (FLLs). METHODS Thirty-nine patients (15 men and 24 women; mean age, 55.4 years) with 39 FLLs (mean size, 3.1±1.8 cm; size range, 1 to 8 cm) prospectively underwent 3D-CEUS. Four readers calculated the volume of each lesion in an independent and blinded fashion in two separate sessions by means of a semi-automatic, commercially available proprietary software. The differences in lesion volumes (cm3) among sessions and readers were assessed using the Mann-Whitney U test and the Kruskal-Wallis test. Bland-Altman analysis was also performed. Intraclass correlation coefficients (ICCs) with 95% confidence intervals (95% CIs) were calculated. The statistical significance level was set at P<0.05. RESULTS Among readers, there were no statistically significant differences in the first (P=0.953) and second (P=0.592) reading sessions for volume calculations of the 39 FLLs, with almost perfect inter-reader agreement (ICC values of the first reading session, 0.996; 95% CI, 0.992 to 0.998 and ICC value of the second reading session, 0.994; 95% CI, 0.990 to 0.997, respectively). For each of the four readers, there were no significant differences in volume calculations between the two sessions (P=0.503-0.924), and the intrareader agreement was almost perfect for each reader (R1: ICC, 0.995; 95% CI, 0.991 to 0.998; R2: ICC, 0.995; 95% CI, 0.988 to 0.997; R3: ICC, 0.996; 95% CI, 0.992 to 0.998; R4: ICC, 0.985; 95% CI, 0.971 to 0.992). CONCLUSION 3D-CEUS volume calculations provided consistent measurements across different readers with almost perfect intrareader agreement.
Collapse
Affiliation(s)
- Tommaso Vincenzo Bartolotta
- Section of Radiology - BiND, University Hospital "Paolo Giaccone", Palermo, Italy.,Department of Radiology, Fondazione Istituto Giuseppe Giglio, Palermo, Italy
| | - Antonio Sidoti Pinto
- Section of Radiology - BiND, University Hospital "Paolo Giaccone", Palermo, Italy
| | - Roberto Cannella
- Section of Radiology - BiND, University Hospital "Paolo Giaccone", Palermo, Italy
| | - Giorgia Porrello
- Section of Radiology - BiND, University Hospital "Paolo Giaccone", Palermo, Italy
| | - Rossana Taravella
- Section of Radiology - BiND, University Hospital "Paolo Giaccone", Palermo, Italy
| | - Angelo Randazzo
- Section of Radiology - BiND, University Hospital "Paolo Giaccone", Palermo, Italy
| | - Adele Taibbi
- Section of Radiology - BiND, University Hospital "Paolo Giaccone", Palermo, Italy
| |
Collapse
|
11
|
Semiautomatic Segmentation and Radiomics for Dual-Energy CT: A Pilot Study to Differentiate Benign and Malignant Hepatic Lesions. AJR Am J Roentgenol 2020; 215:398-405. [PMID: 32406776 DOI: 10.2214/ajr.19.22164] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE. This study assessed a machine learning-based dual-energy CT (DECT) tumor analysis prototype for semiautomatic segmentation and radiomic analysis of benign and malignant liver lesions seen on contrast-enhanced DECT. MATERIALS AND METHODS. This institutional review board-approved study included 103 adult patients (mean age, 65 ± 15 [SD] years; 53 men, 50 women) with benign (60/103) or malignant (43/103) hepatic lesions on contrast-enhanced dual-source DECT. Most malignant lesions were histologically proven; benign lesions were either stable on follow-up CT or had characteristic benign features on MRI. Low- and high-kilovoltage datasets were deidentified, exported offline, and processed with the DECT tumor analysis for semiautomatic segmentation of the volume and rim of each liver lesion. For each segmentation, contrast enhancement and iodine concentrations as well as radiomic features were derived for different DECT image series. Statistical analyses were performed to determine if DECT tumor analysis and radiomics can differentiate benign from malignant liver lesions. RESULTS. Normalized iodine concentration and mean iodine concentration in the benign and malignant lesions were significantly different (p < 0.0001-0.0084; AUC, 0.695-0.856). Iodine quantification and radiomic features from lesion rims (AUC, ≤ 0.877) had higher accuracy for differentiating liver lesions compared with the values from lesion volumes (AUC, ≤ 0.856). There was no difference in the accuracies of DECT iodine quantification (AUC, 0.91) and radiomics (AUC, 0.90) for characterizing liver lesions. CONCLUSION. DECT radiomics were more accurate than iodine quantification for differentiating solid benign and malignant hepatic lesions.
Collapse
|
12
|
Abstract
The Quantitative Imaging Network of the National Cancer Institute is in its 10th year of operation, and research teams within the network are developing and validating clinical decision support software tools to measure or predict the response of cancers to various therapies. As projects progress from development activities to validation of quantitative imaging tools and methods, it is important to evaluate the performance and clinical readiness of the tools before committing them to prospective clinical trials. A variety of tests, including special challenges and tool benchmarking, have been instituted within the network to prepare the quantitative imaging tools for service in clinical trials. This article highlights the benchmarking process and provides a current evaluation of several tools in their transition from development to validation.
Collapse
Affiliation(s)
- Keyvan Farahani
- Cancer Imaging Program, National Cancer Institute of NIH, Bethesda, MD
| | - Darrell Tata
- Cancer Imaging Program, National Cancer Institute of NIH, Bethesda, MD
| | | |
Collapse
|
13
|
Tang W, Zou D, Yang S, Shi J, Dan J, Song G. A two-stage approach for automatic liver segmentation with Faster R-CNN and DeepLab. Neural Comput Appl 2020. [DOI: 10.1007/s00521-019-04700-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
14
|
Chen L, Song H, Wang C, Cui Y, Yang J, Hu X, Zhang L. Liver tumor segmentation in CT volumes using an adversarial densely connected network. BMC Bioinformatics 2019; 20:587. [PMID: 31787071 PMCID: PMC6886252 DOI: 10.1186/s12859-019-3069-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Background Malignant liver tumor is one of the main causes of human death. In order to help physician better diagnose and make personalized treatment schemes, in clinical practice, it is often necessary to segment and visualize the liver tumor from abdominal computed tomography images. Due to the large number of slices in computed tomography sequence, developing an automatic and reliable segmentation method is very favored by physicians. However, because of the noise existed in the scan sequence and the similar pixel intensity of liver tumors with their surrounding tissues, besides, the size, position and shape of tumors also vary from one patient to another, automatic liver tumor segmentation is still a difficult task. Results We perform the proposed algorithm to the Liver Tumor Segmentation Challenge dataset and evaluate the segmentation results. Experimental results reveal that the proposed method achieved an average Dice score of 68.4% for tumor segmentation by using the designed network, and ASD, MSD, VOE and RVD improved from 27.8 to 21, 147 to 124, 0.52 to 0.46 and 0.69 to 0.73, respectively after performing adversarial training strategy, which proved the effectiveness of the proposed method. Conclusions The testing results show that the proposed method achieves improved performance, which corroborated the adversarial training based strategy can achieve more accurate and robustness results on liver tumor segmentation task.
Collapse
Affiliation(s)
- Lei Chen
- School of Computer Science & Technology, Beijing Institute of Technology, 5 South Zhongguancun Street, Beijing, 100081, China
| | - Hong Song
- School of Computer Science & Technology, Beijing Institute of Technology, 5 South Zhongguancun Street, Beijing, 100081, China.
| | - Chi Wang
- School of Computer Science & Technology, Beijing Institute of Technology, 5 South Zhongguancun Street, Beijing, 100081, China
| | - Yutao Cui
- School of Computer Science & Technology, Beijing Institute of Technology, 5 South Zhongguancun Street, Beijing, 100081, China
| | - Jian Yang
- School of Optics and Electronics & Technology, Beijing Institute of Technology, 5 South Zhongguancun Street, Beijing, 100081, China
| | - Xiaohua Hu
- College of Computing & Informatics, Drexel University, Philadelphia, PA, USA
| | - Le Zhang
- College of Computer Science, Sichuan University, Chengdu, China
| |
Collapse
|
15
|
Dercle L, Connors DE, Tang Y, Adam SJ, Gönen M, Hilden P, Karovic S, Maitland M, Moskowitz CS, Kelloff G, Zhao B, Oxnard GR, Schwartz LH. Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology. JCO Clin Cancer Inform 2019; 2:1-12. [PMID: 30652552 DOI: 10.1200/cci.17.00137] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE To develop a public-private partnership to study the feasibility of a new approach in collecting and analyzing clinically annotated imaging data from landmark phase III trials in advanced solid tumors. PATIENTS AND METHODS The collection of clinical trials fulfilled the following inclusion criteria: completed randomized trials of > 300 patients, highly measurable solid tumors (non-small-cell lung cancer, colorectal cancer, renal cell cancer, and melanoma), and required sponsor and institutional review board sign-offs. The new approach in analyzing computed tomography scans was to transfer to an academic image analysis laboratory, draw contours semi-automatically by using in-house-developed algorithms integrated into the open source imaging platform Weasis, and perform serial volumetric measurement. RESULTS The median duration of contracting with five sponsors was 12 months. Ten trials in 7,085 patients that covered 12 treatment regimens across 20 trial arms were collected. To date, four trials in 3,954 patients were analyzed. Source imaging data were transferred to the academic core from 97% of trial patients (n = 3,837). Tumor imaging measurements were extracted from 82% of transferred computed tomography scans (n = 3,162). Causes of extraction failure were nonmeasurable disease (n = 392), single imaging time point (n = 224), and secondary captured images (n = 59). Overall, clinically annotated imaging data were extracted in 79% of patients (n = 3,055), and the primary trial end point analysis in each trial remained representative of each original trial end point. CONCLUSION The sharing and analysis of source imaging data from large randomized trials is feasible and offer a rich and reusable, but largely untapped, resource for future research on novel trial-level response and progression imaging metrics.
Collapse
Affiliation(s)
- Laurent Dercle
- Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - Dana E Connors
- Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - Ying Tang
- Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - Stacey J Adam
- Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - Mithat Gönen
- Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - Patrick Hilden
- Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - Sanja Karovic
- Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - Michael Maitland
- Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - Chaya S Moskowitz
- Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - Gary Kelloff
- Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - Binsheng Zhao
- Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - Geoffrey R Oxnard
- Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - Lawrence H Schwartz
- Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| |
Collapse
|
16
|
Deng Z, Guo Q, Zhu Z. Dynamic Regulation of Level Set Parameters Using 3D Convolutional Neural Network for Liver Tumor Segmentation. JOURNAL OF HEALTHCARE ENGINEERING 2019; 2019:4321645. [PMID: 30918620 PMCID: PMC6409057 DOI: 10.1155/2019/4321645] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Accepted: 02/06/2019] [Indexed: 02/07/2023]
Abstract
Segmentation of liver tumors plays an important role in the choice of therapeutic strategies for liver disease and treatment monitoring. In this paper, we generalize the process of a level set with a novel algorithm of dynamic regulation to energy functional parameters. The presented method is fully automatic once the tumor has been detected. First, a 3D convolutional neural network with dense layers for classification is used to estimate current contour location relative to the tumor boundary. Second, the output 3D CNN probabilities can dynamically regulate parameters of the level set functional over the process of segmentation. Finally, for full automation, appropriate initializations and local window size are generated based on the current contour position probabilities. We demonstrate the proposed method on the dataset of MICCAI 2017 LiTS Challenge and 3DIRCADb that include low contrast and heterogeneous tumors as well as noisy images. To illustrate the strength of our method, we evaluated it against the state-of-the-art methods. Compared with the level set framework with fixed parameters, our method performed better significantly with an average DICE improvement of 0.15. We also analyzed a challenging dataset 3DIRCADb of tumors and obtained a competitive DICE of 0.85 ± 0.06 with the proposed method.
Collapse
Affiliation(s)
- Zhuofu Deng
- College of Software, Northeastern University, Shenyang 110004, China
| | - Qingzhe Guo
- College of Software, Northeastern University, Shenyang 110004, China
| | - Zhiliang Zhu
- College of Software, Northeastern University, Shenyang 110004, China
| |
Collapse
|
17
|
Malekpour M, Widom K, Dove J, Blansfield J, Shabahang M, Torres D, Wild JL. Management of computed tomography scan detected hemothorax in blunt chest trauma: What computed tomography scan measurements say? World J Radiol 2018; 10:184-189. [PMID: 30631406 PMCID: PMC6323492 DOI: 10.4329/wjr.v10.i12.184] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Revised: 09/17/2018] [Accepted: 10/24/2018] [Indexed: 02/06/2023] Open
Abstract
AIM To investigate the hemothorax size for which tube thoracostomy is necessary.
METHODS Over a 5-year period, we included all patients who were admitted with blunt chest trauma to our level 1 trauma center. Focus was placed on identifying the hemothorax size requiring tube thoracostomy.
RESULTS A total number of 274 hemothoraces were studied. All patients with hemothoraces measuring above 3 cm received a chest tube. The 50% predicted probability of tube thoracostomy was 2 cm. Pneumothorax was associated with odds of receiving tube thoracostomy for hemothoraces below 2 cm (Odds Ratio: 4.967, 95%CI: 2.225-11.097, P < 0.0001).
CONCLUSION All patients with a hemothorax size greater than 3% underwent tube thoracostomy. Prospective studies are warranted to elucidate the clinical outcome of patients with smaller hemothoraces.
Collapse
Affiliation(s)
- Mahdi Malekpour
- Department of Surgery, Section of Trauma and Acute Care Surgery, Geisinger Medical Center, Danville, PA 17822, United States
| | - Kenneth Widom
- Department of Surgery, Section of Trauma and Acute Care Surgery, Geisinger Medical Center, Danville, PA 17822, United States
| | - James Dove
- Department of Surgery, Section of Trauma and Acute Care Surgery, Geisinger Medical Center, Danville, PA 17822, United States
| | - Joseph Blansfield
- Department of Surgery, Section of Trauma and Acute Care Surgery, Geisinger Medical Center, Danville, PA 17822, United States
| | - Mohsen Shabahang
- Department of Surgery, Section of Trauma and Acute Care Surgery, Geisinger Medical Center, Danville, PA 17822, United States
| | - Denise Torres
- Department of Surgery, Section of Trauma and Acute Care Surgery, Geisinger Medical Center, Danville, PA 17822, United States
| | - Jeffrey L Wild
- Department of Surgery, Section of Trauma and Acute Care Surgery, Geisinger Medical Center, Danville, PA 17822, United States
| |
Collapse
|
18
|
Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study. Cancer Chemother Pharmacol 2018; 82:49-54. [PMID: 29700575 DOI: 10.1007/s00280-018-3587-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Accepted: 04/20/2018] [Indexed: 12/15/2022]
Abstract
PURPOSE To compare lesion-level and volumetric measures of tumor burden with sum of the longest dimensions (SLD) of target lesions on overall survival (OS) predictions using time-to-growth (TTG) as predictor. METHODS Tumor burden and OS data from a phase 3 randomized study of second-line FOLFIRI ± aflibercept in metastatic colorectal cancer were available for 918 patients out of 1216 treated (75%). A TGI model that estimates TTG was fit to the longitudinal tumor size data (nonlinear mixed effect modeling) to estimate TTG with: SLD, sum of the measured lesion volumes (SV), individual lesion diameters (ILD), or individual lesion volumes (ILV). A parametric OS model was built with TTG estimates and assessed for prediction of the hazard ratio (HR) for survival. RESULTS Individual lesions had consistent dynamics within individuals. Between-lesion variability in rate constants was lower (typically < 27% CV) than inter-patient variability (typically > 50% CV). Estimates of TTG were consistent (around 12 weeks) across tumor size assessments. TTG was highly significant in a log-logistic parametric model of OS (median over 12 months). When individual lesions were considered, TTG of the fastest progressing lesions best predicted OS. TTG obtained from the lesion-level analyses were slightly better predictors of OS than estimates from the sums, with ILV marginally better than ILD. All models predicted VELOUR HR equally well and all predicted study success. CONCLUSION This analysis revealed consistent TGI profiles across all tumor size assessments considered. TTG predicted VELOUR HR when based on any of the tumor size measures.
Collapse
|
19
|
Baâzaoui A, Barhoumi W, Ahmed A, Zagrouba E. Semi-Automated Segmentation of Single and Multiple Tumors in Liver CT Images Using Entropy-Based Fuzzy Region Growing. Ing Rech Biomed 2017. [DOI: 10.1016/j.irbm.2017.02.003] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
20
|
Sun C, Guo S, Zhang H, Li J, Chen M, Ma S, Jin L, Liu X, Li X, Qian X. Automatic segmentation of liver tumors from multiphase contrast-enhanced CT images based on FCNs. Artif Intell Med 2017; 83:58-66. [PMID: 28347562 DOI: 10.1016/j.artmed.2017.03.008] [Citation(s) in RCA: 85] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2016] [Revised: 02/28/2017] [Accepted: 03/10/2017] [Indexed: 02/07/2023]
Abstract
This paper presents a novel, fully automatic approach based on a fully convolutional network (FCN) for segmenting liver tumors from CT images. Specifically, we designed a multi-channel fully convolutional network (MC-FCN) to segment liver tumors from multiphase contrast-enhanced CT images. Because each phase of contrast-enhanced data provides distinct information on pathological features, we trained one network for each phase of the CT images and fused their high-layer features together. The proposed approach was validated on CT images taken from two databases: 3Dircadb and JDRD. In the case of 3Dircadb, using the FCN, the mean ratios of the volumetric overlap error (VOE), relative volume difference (RVD), average symmetric surface distance (ASD), root mean square symmetric surface distance (RMSD) and maximum symmetric surface distance (MSSD) were 15.6±4.3%, 5.8±3.5%, 2.0±0.9%, 2.9±1.5mm, 7.1±6.2mm, respectively. For JDRD, using the MC-FCN, the mean ratios of VOE, RVD, ASD, RMSD, and MSSD were 8.1±4.5%, 1.7±1.0%, 1.5±0.7%, 2.0±1.2mm, 5.2±6.4mm, respectively. The test results demonstrate that the MC-FCN model provides greater accuracy and robustness than previous methods.
Collapse
Affiliation(s)
- Changjian Sun
- College of Electronic Science and Engineering, Jilin University, Changchun, China
| | - Shuxu Guo
- College of Electronic Science and Engineering, Jilin University, Changchun, China
| | - Huimao Zhang
- Radiology, The First Hospital of Jilin University, Changchun, China
| | - Jing Li
- Radiology, The First Hospital of Jilin University, Changchun, China
| | - Meimei Chen
- College of Communication Engineering, Jilin University, Changchun, China
| | - Shuzhi Ma
- College of Electronic Science and Engineering, Jilin University, Changchun, China
| | - Lanyi Jin
- College of Electronic Science and Engineering, Jilin University, Changchun, China
| | - Xiaoming Liu
- College of Electronic Science and Engineering, Jilin University, Changchun, China
| | - Xueyan Li
- College of Electronic Science and Engineering, Jilin University, Changchun, China.
| | - Xiaohua Qian
- Radiology, Wake Forest School of Medicine, Winston Salem, USA.
| |
Collapse
|
21
|
Li Q, Liang Y, Huang Q, Zong M, Berman B, Gavrielides MA, Schwartz LH, Zhao B, Petrick N. Volumetry of low-contrast liver lesions with CT: Investigation of estimation uncertainties in a phantom study. Med Phys 2017; 43:6608. [PMID: 27908157 DOI: 10.1118/1.4967776] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE To evaluate the performance of lesion volumetry in hepatic CT as a function of various imaging acquisition parameters. METHODS An anthropomorphic abdominal phantom with removable liver inserts was designed for this study. Two liver inserts, each containing 19 synthetic lesions with varying diameter (6-40 mm), shape, contrast (10-65 HU), and both homogenous and mixed-density were designed to have background and lesion CT values corresponding to arterial and portal-venous phase imaging, respectively. The two phantoms were scanned using two commercial CT scanners (GE 750 HD and Siemens Biograph mCT) across a set of imaging protocols (four slice thicknesses, three effective mAs, two convolution kernels, two pitches). Two repeated scans were collected for each imaging protocol. All scans were analyzed using a matched-filter estimator for volume estimation, resulting in 6080 volume measurements across all of the synthetic lesions in the two liver phantoms. A subset of portal venous phase scans was also analyzed using a semi-automatic segmentation algorithm, resulting in about 900 additional volume measurements. Lesions associated with large measurement error (quantified by root mean square error) for most imaging protocols were considered not measurable by the volume estimation tools and excluded for the statistical analyses. Imaging protocols were grouped into distinct imaging conditions based on ANOVA analysis of factors for repeatability testing. Statistical analyses, including overall linearity analysis, grouped bias analysis with standard deviation evaluation, and repeatability analysis, were performed to assess the accuracy and precision of the liver lesion volume biomarker. RESULTS Lesions with lower contrast and size ≤10 mm were associated with higher measurement error and were excluded from further analysis. Lesion size, contrast, imaging slice thickness, dose, and scanner were found to be factors substantially influencing volume estimation. Twenty-four distinct repeatable imaging conditions were determined as protocols for each scanner with a fixed slice thickness and dose. For the matched-filter estimation approach, strong linearity was observed for all imaging data for lesions ≥20 mm. For the Siemens scanner with 50 mAs effective dose at 0.6 mm slice thickness, grouped bias was about -10%. For all other repeatable imaging conditions with both scanners, grouped biases were low (-3%-3%). There was a trend of increasing standard deviation with decreasing dose. For each fixed dose, the standard deviations were similar among the three larger slice thicknesses (1.25, 2.5, 5 mm for GE, 1.5, 3, 5 mm for Siemens). Repeatability coefficients ranged from about 8% to 75% and showed similar trend to grouped standard deviation. For the segmentation approach, the results led to similar conclusions for both lesion characteristic factors and imaging factors but with increasing magnitude in all the error metrics assessed. CONCLUSIONS Results showed that liver lesion volumetry was strongly dependent on lesion size, contrast, acquisition dose, and their interactions. The overall performances were similar for images reconstructed with larger slice thicknesses, clinically used pitches, kernels, and doses. Conditions that yielded repeatable measurements were identified and they agreed with the Quantitative Imaging Biomarker Alliance's (QIBA) profile requirements in general. The authors' findings also suggest potential refinements to these guidelines for the tumor volume biomarker, especially for soft-tissue lesions.
Collapse
Affiliation(s)
- Qin Li
- Division of Imaging, Diagnostics and Software Reliability, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, Maryland 20993
| | - Yongguang Liang
- Department of Radiology, Columbia University Medical Center, New York, New York 10032
| | - Qiao Huang
- Department of Radiology, Columbia University Medical Center, New York, New York 10032
| | - Min Zong
- Department of Radiology, Columbia University Medical Center, New York, New York 10032
| | - Benjamin Berman
- Division of Imaging, Diagnostics and Software Reliability, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, Maryland 20993
| | - Marios A Gavrielides
- Division of Imaging, Diagnostics and Software Reliability, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, Maryland 20993
| | - Lawrence H Schwartz
- Department of Radiology, Columbia University Medical Center, New York, New York 10032
| | - Binsheng Zhao
- Department of Radiology, Columbia University Medical Center, New York, New York 10032
| | - Nicholas Petrick
- Division of Imaging, Diagnostics and Software Reliability, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, Maryland 20993
| |
Collapse
|
22
|
Hoogi A, Beaulieu CF, Cunha GM, Heba E, Sirlin CB, Napel S, Rubin DL. Adaptive local window for level set segmentation of CT and MRI liver lesions. Med Image Anal 2017; 37:46-55. [PMID: 28157660 DOI: 10.1016/j.media.2017.01.002] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2016] [Revised: 12/18/2016] [Accepted: 01/05/2017] [Indexed: 11/18/2022]
Abstract
We propose a novel method, the adaptive local window, for improving level set segmentation technique. The window is estimated separately for each contour point, over iterations of the segmentation process, and for each individual object. Our method considers the object scale, the spatial texture, and the changes of the energy functional over iterations. Global and local statistics are considered by calculating several gray level co-occurrence matrices. We demonstrate the capabilities of the method in the domain of medical imaging for segmenting 233 images with liver lesions. To illustrate the strength of our method, those lesions were screened by either Computed Tomography or Magnetic Resonance Imaging. Moreover, we analyzed images using three different energy models. We compared our method to a global level set segmentation, to a local framework that uses predefined fixed-size square windows and to a local region-scalable fitting model. The results indicate that our proposed method outperforms the other methods in terms of agreement with the manual marking and dependence on contour initialization or the energy model used. In case of complex lesions, such as low contrast lesions, heterogeneous lesions, or lesions with a noisy background, our method shows significantly better segmentation with an improvement of 0.25 ± 0.13 in Dice similarity coefficient, compared with state of the art fixed-size local windows (Wilcoxon, p < 0.001).
Collapse
Affiliation(s)
- Assaf Hoogi
- Departments of Radiology and Medicine (Biomedical Informatics Research), Stanford University, Stanford, CA, USA.
| | - Christopher F Beaulieu
- Department of Radiology and, by courtesy, Orthopedic Surgery, Stanford University, Stanford, CA, USA.
| | - Guilherme M Cunha
- Department of Radiology, University of California, San Diego Medical Center, San Diego, CA, USA.
| | - Elhamy Heba
- Department of Radiology, University of California, San Diego Medical Center, San Diego, CA, USA.
| | - Claude B Sirlin
- Department of Radiology, University of California, San Diego Medical Center, San Diego, CA, USA.
| | - Sandy Napel
- Department of Radiology and, by courtesy, Electrical Engineering and Medicine, Stanford University, Stanford, CA, USA.
| | - Daniel L Rubin
- Departments of Radiology and Medicine (Biomedical Informatics Research), Stanford University, Stanford, CA, USA.
| |
Collapse
|
23
|
Yang H, Schwartz LH, Zhao B. A Response Assessment Platform for Development and Validation of Imaging Biomarkers in Oncology. ACTA ACUST UNITED AC 2016; 2:406-410. [PMID: 30042969 PMCID: PMC6037929 DOI: 10.18383/j.tom.2016.00223] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Quantitative imaging biomarkers are increasingly used in both oncology clinical trials and clinical practice aid evaluation of tumor response to novel therapies. To obtain these biomarkers, and to ensure smooth clinical adoption once they have been validated, it is critical to develop reliable computer-aided methods and a workflow-efficient imaging platform for integration in research and clinical settings. Here, we present a volumetric response assessment system developed based on an open-source image-viewing platform (WEASIS). Our response assessment system is designed using the Model–View–Controller concept, and it offers standard image-viewing and -manipulation functions, efficient tumor segmentation and quantification algorithms, and a reliable database containing tumor segmentation and measurement results. This prototype system is currently used in our research laboratory to foster the development and validation of new quantitative imaging biomarkers including the volumetric computed tomography technique as a more accurate and early assessment method of solid tumor response to targeted therapy and immunotherapy.
Collapse
Affiliation(s)
- Hao Yang
- Department of Radiology, Columbia University Medical Center, New York, New York
| | - Lawrence H Schwartz
- Department of Radiology, Columbia University Medical Center, New York, New York
| | - Binsheng Zhao
- Department of Radiology, Columbia University Medical Center, New York, New York
| |
Collapse
|